Flow Cytometric Assessment of Malignant Hematologic Disorders
Authors:
- 30 May 2024
- journal article
- research article
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 44 (3) , 465-477
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapyCytometry Part B: Clinical Cytometry, 2023
- Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issuesCytometry Part B: Clinical Cytometry, 2022
- Measurable Residual Disease Detection in B‐Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) MethodCurrent Protocols, 2022
- Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal ApproachCurrent Protocols in Cytometry, 2020
- Single Antibody Detection of T‐Cell Receptor αβ Clonality by Flow Cytometry Rapidly Identifies Mature T‐Cell Neoplasms and Monotypic Small CD8‐Positive Subsets of Uncertain SignificanceCytometry Part B: Clinical Cytometry, 2019
- Flow Cytometry: An OverviewCurrent Protocols in Immunology, 2018
- Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometryCytometry Part B: Clinical Cytometry, 2015
- Tumor heterogeneity makes AML a “moving target” for detection of residual diseaseCytometry Part B: Clinical Cytometry, 2013
- Myeloid Malignancies: Myelodysplastic Syndromes, Myeloproliferative Disorders, and Acute Myeloid LeukemiaClinics In Laboratory Medicine, 2007
- 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: Medical indicationsCytometry Part B: Clinical Cytometry, 2007